Browse by People

Up a level
Export as [feed] Atom [feed] RSS [feed] RSSPD
Group by: Item Type | No Grouping
Number of items: 3.

Morris, K.A., Golding, J.F., Blesing, C., Evans, D.G., Ferner, R.E., Foweraker, K., Halliday, D., Jena, R., McBain, C., McCabe, M.G., Swampillai, A., Warner, N., Wilson, S., Parry, A. and Afridi, S. (2016) Toxicity profile of bevacizumab in the UK Neurofibromatosis Type 2 cohort. Journal of Neuro-oncology. ISSN 0167-594X (In Press)
[img]

Ferner, R.E., Shaw, A., Evans, D.G., McAleer, D., Halliday, D., Parry, A., Raymond F, L., Durie-Gair, J., Hanemann C, O., Hornigold, R., Axon, P.R. and Golding, J.F. (2014) Longitudinal evaluation of quality of life in 288 patients with Neurofibromatosis 2. Journal of Neurology, 26 (5). pp. 936-969. ISSN 0340-5354
[img]

Ferner, R.E., Golding, John F., Smith, M., Calonje, E., Jan, W., Sanjayanathan, V. and O'Doherty, M. (2008) [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical study. Annals of Oncology, 19 (2). pp. 390-394. ISSN 0923-7534

This list was generated on Tue Aug 30 23:34:23 2016 BST.